Author(s): Insel TR, Insel TR
Abstract Share this page
Abstract There has been a steady retreat by the private sector away from developing medications for mental disorders. This retreat comes just as research is identifying new molecular targets, new clinical targets, and new uses of current treatments that may serve as the basis for the next generation of treatments for mental disorders.
This article was published in Sci Transl Med
and referenced in Drug Designing: Open Access